Arkolith/Insider Trading/ANTX/Form 4

Chanda Sanjay

Chief Development OfficerAN2 Therapeutics, Inc. (ANTX) · full profile →Form 4 · filed Mar 23, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 19, 2026Disposed to issuer(D)66K——0
Mar 19, 2026Grant(A)58K——58K
Mar 19, 2026Disposed to issuer(D)58K——0
Mar 19, 2026Grant(A)42K——42K
Mar 19, 2026Disposed to issuer(D)42K——0
Mar 19, 2026Grant(A)66K——66K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-120235) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML